Quantcast
Last updated on April 18, 2014 at 5:48 EDT

BD Announces Results For 2013 Third Fiscal Quarter

August 1, 2013

– Reports solid third fiscal quarter revenues of $2.053 billion, an increase of 3.6 percent, or 5.1 percent on a foreign currency-neutral basis.

FRANKLIN LAKES, N.J., Aug. 1, 2013 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.053 billion for the third fiscal quarter ended June 30, 2013, representing an increase of 3.6 percent from the prior-year period, or 5.1 percent on a foreign currency-neutral basis.

“Our solid results against the backdrop of a challenging environment demonstrate that we are executing on our strategy and delivering on our commitments,” said Vincent A. Forlenza, Chairman, CEO and President. “We remain confident in our fiscal year 2013 outlook.”

Third Quarter and Nine-Month Fiscal 2013 Operating Results
Diluted earnings per share from continuing operations for the third quarter were $1.47, compared with $1.52 in the prior-year period, representing a 3.3 percent decrease, or flat on a foreign currency-neutral basis. Current quarter results include a charge of $22 million, or $0.07 per share from continuing operations, due to a pending antitrust class action settlement. The resulting adjusted diluted earnings per share from continuing operations were $1.54. The adjusted diluted earnings per share from continuing operations without the medical device excise tax, which went into effect in January 2013 under the U.S. healthcare reform law, were $1.58. This represents growth of 7.2 percent on a foreign currency-neutral basis.

For the nine-month period ending June 30, 2013, diluted earnings per share from continuing operations were $4.21, compared with $3.95 in the prior-year period. This represents growth of 6.6 percent, or 7.8 percent on a foreign currency-neutral basis. The adjusted diluted earnings per share from continuing operations without the medical device excise tax were $4.37. This represents growth of 11.9 percent on a foreign currency-neutral basis.

Segment Results
In the BD Medical segment, worldwide revenues for the quarter were $1.140 billion, representing an increase of 6.6 percent compared with the prior-year period, or 7.9 percent on a foreign currency-neutral basis. The segment’s revenue growth reflects strong sales across all three business units. As expected, the segment’s growth was partially aided by the reversal of an unfavorable timing of orders in the second quarter in both Pharmaceutical Systems and Diabetes Care. For the nine-month period ended June 30, 2013, BD Medical revenues increased 4.7 percent, or 5.8 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $655 million, representing an increase of 2.0 percent compared with the prior-year period, or 3.6 percent on a foreign currency-neutral basis. The segment’s growth was driven by solid sales in the Preanalytical Systems unit, partially offset by ongoing softness in Women’s Health and Cancer in the U.S. For the nine-month period ended June 30, 2013, BD Diagnostics revenues increased 3.9 percent, or 4.9 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $257 million, representing a decrease of 4.2 percent compared with the prior-year period, or a decrease of 2.5 percent on a foreign currency-neutral basis. Instrument placements in the U.S. were more than offset by softness in Western Europe due to austerity measures, continued delays of government funding in Japan, and timing of orders in Advanced Bioprocessing. For the nine-month period ended June 30, 2013, BD Biosciences revenues decreased 0.6 percent, or an increase of 0.9 percent on a currency-neutral basis.

Geographic Results
Third quarter revenues in the U.S. of $848 million represent an increase of 1.3 percent over the prior-year period. As expected, U.S. revenues were unfavorably impacted by a timing of orders in Advanced Bioprocessing and the aforementioned softness in Women’s Health and Cancer. Revenues outside of the U.S. were $1.205 billion, representing an increase of 5.3 percent compared with the prior-year period, or 7.9 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and strong sales of safety-engineered products.

For the nine-month period ended June 30, 2013, revenues in the U.S. were $2.501 billion, representing an increase of 1.5 percent compared with the prior-year period. Revenues outside of the U.S. were $3.452 billion, representing an increase of 5.3 percent compared with the prior-year period, or 7.3 percent on a foreign currency-neutral basis.

Fiscal 2013 Outlook for Full Year
The Company is reaffirming its previously communicated guidance for the full fiscal year 2013 on revenues and earnings per share growth. On a currency-neutral basis, revenue growth is expected to approach 5.0 percent, which is the upper end of the Company’s previously communicated guidance range. Reported revenue growth is expected to be between 3.5 to 4.0 percent. Earnings per share from continuing operations for fiscal year 2013 are expected to be between $5.65 and $5.68, or $5.72 and $5.75 after adjusting for a pending antitrust class action settlement. This represents growth of 6.5 to 7.0 percent over 2012 adjusted diluted earnings per share of $5.37, which excludes a pension settlement charge, in fiscal year 2012. On a currency-neutral basis, adjusted earnings per share growth is expected to be between 8.5 to 9.0 percent. After adjusting for the impact of the medical device excise tax and foreign currency, adjusted diluted earnings per share are expected to grow at the upper end of the Company’s previously communicated guidance range of 11.0 to 11.5 percent. In line with previously disclosed guidance, the Company plans to repurchase, subject to market conditions, up to $500 million of its common stock in fiscal year 2013.

Conference Call Information
A conference call regarding BD’s third quarter results will be broadcast live on BD’s website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Thursday, August 1, 2013. The conference call will be available for replay on BD’s website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Thursday, August 8, 2013, confirmation number 15535210.

Non-GAAP Financial Measures
This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

***

This press release, including the section entitled “Fiscal 2013 Outlook for Full Year”, contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD’s performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures, including “sequestration”, which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers’ ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD’s products; fluctuations in costs and availability of raw materials and in BD’s ability to maintain favorable supplier arrangements and relationships; the adverse impact of cyber-attacks on our information systems; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD’s filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD’s filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact:
Monique N. Dolecki, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

    BECTON DICKINSON AND COMPANY

    CONSOLIDATED INCOME STATEMENTS

    (Unaudited; Amounts in thousands, except per share data)

                                                                                     Three Months Ended June 30,

                                                                                                        2013             2012   % Change
                                                                                                      ----             ----   --------

    REVENUES                                                                                    $2,052,664       $1,980,530         3.6

    Cost of products sold                                                                          992,673          947,395         4.8

    Selling and administrative                                                                     534,320          469,130        13.9

    Research and development                                                                       121,116          114,987         5.3
    ------------------------                                                                       -------          -------         ---

    TOTAL OPERATING COSTS

         AND EXPENSES                                                                            1,648,109        1,531,512         7.6
         ------------                                                                            ---------        ---------         ---

    OPERATING INCOME                                                                               404,555          449,018        (9.9)

    Interest income                                                                                  6,272            6,253         0.3

    Interest expense                                                                               (34,573)         (34,849)       (0.8)

    Other income (expense), net                                                                      2,809           (1,881)         NM
    ---------------------------                                                                      -----           ------         ---

    INCOME FROM CONTINUING OPERATIONS BEFORE

         INCOME TAXES                                                                              379,063          418,541        (9.4)

    Income tax provision                                                                            87,185          106,960       (18.5)
    --------------------                                                                            ------          -------       -----

    INCOME FROM CONTINUING OPERATIONS                                                              291,878          311,581        (6.3)

    INCOME FROM DISCONTINUED OPERATIONS

       NET OF INCOME TAX PROVISION OF

                                                             $6,432 AND $7,288, RESPECTIVELY         9,672           15,285       (36.7)
                                                             -------------------------------         -----           ------       -----

    NET INCOME                                                                                    $301,550         $326,866        (7.7)
    ----------                                                                                    --------         --------        ----

    EARNINGS PER SHARE

    Basic:

    Income from continuing operations                                                                $1.50            $1.54        (2.6)

    Income from discontinued operations                                                              $0.05            $0.08       (37.5)

    Net income                                                                                       $1.55            $1.62        (4.3)

    Diluted:

    Income from continuing operations                                                                $1.47            $1.52        (3.3)

    Income from discontinued operations                                                              $0.05            $0.07       (28.6)

    Net income                                                                                       $1.52            $1.59        (4.4)

    AVERAGE SHARES OUTSTANDING

         Basic                                                                                     194,879          202,015

         Diluted                                                                                   198,719          205,290
         -------                                                                                   -------          -------

    NM - Not Meaningful

    BECTON DICKINSON AND COMPANY

    CONSOLIDATED INCOME STATEMENTS

    (Unaudited; Amounts in thousands, except per share data)

                                                                                                Nine Months Ended June 30,

                                                                                                         2013                     2012   % Change
                                                                                                       ----                     ----   --------

    REVENUES                                                                                     $5,953,232               $5,741,211         3.7

    Cost of products sold                                                                         2,868,993                2,789,044         2.9

    Selling and administrative                                                                    1,544,808                1,439,094         7.3

    Research and development                                                                        361,654                  343,968         5.1
    ------------------------                                                                        -------                  -------         ---

    TOTAL OPERATING COSTS

         AND EXPENSES                                                                             4,775,455                4,572,106         4.4
         ------------                                                                             ---------                ---------         ---

    OPERATING INCOME                                                                              1,177,777                1,169,105         0.7

    Interest income                                                                                  26,012                   38,379       (32.2)

    Interest expense                                                                               (104,334)                 (99,367)        5.0

    Other income, net                                                                                 5,775                    2,392          NM
    -----------------                                                                                 -----                    -----         ---

    INCOME FROM CONTINUING OPERATIONS BEFORE

         INCOME TAXES                                                                             1,105,230                1,110,509        (0.5)

    Income tax provision                                                                            266,982                  275,260        (3.0)
    --------------------                                                                            -------                  -------        ----

    INCOME FROM CONTINUING OPERATIONS                                                               838,248                  835,249         0.4

    INCOME FROM DISCONTINUED OPERATIONS

       NET OF INCOME TAX PROVISION OF

                                                             $221,592 AND $22,158, RESPECTIVELY     364,375                   45,635          NM
                                                             ----------------------------------     -------                   ------         ---

    NET INCOME                                                                                   $1,202,623                 $880,884        36.5
    ----------                                                                                   ----------                 --------        ----

    EARNINGS PER SHARE

    Basic:

    Income from continuing operations                                                                 $4.29                    $4.02         6.7

    Income from discontinued operations                                                               $1.87                    $0.22          NM

    Net income                                                                                        $6.16                    $4.24        45.3

    Diluted:

    Income from continuing operations                                                                 $4.21                    $3.95         6.6

    Income from discontinued operations                                                               $1.83                    $0.22          NM

    Net income                                                                                        $6.04                    $4.17        44.8

    AVERAGE SHARES OUTSTANDING

         Basic                                                                                      195,312                  207,605

         Diluted                                                                                    199,111                  211,254
         -------                                                                                    -------                  -------

    NM - Not Meaningful

    BECTON
     DICKINSON
     AND
     COMPANY

     SUPPLEMENTAL
     REVENUE
     INFORMATION

    REVENUES
     BY
     SEGMENT
     AND
     GEOGRAPHIC
     AREA

     (Unaudited;
     Amounts
     in
     thousands)

                     Three Months Ended June 30,

                                                   2013       2012 % Change
                                                   ----       ---- --------

    BD MEDICAL
    ----------

       United
        States                                 $448,670   $429,621           4.4

       International                            691,828    640,455           8.0
       -------------                            -------    -------

    TOTAL                                    $1,140,498 $1,070,076           6.6
    -----                                    ---------- ----------           ---

    BD
     DIAGNOSTICS
    ------------

       United
        States                                 $310,386   $315,240          (1.5)

       International                            344,724    327,010           5.4
       -------------                            -------    -------

    TOTAL                                      $655,110   $642,250           2.0
    -----                                      --------   --------           ---

    BD
     BIOSCIENCES
    ------------

       United
        States                                  $88,636    $91,674          (3.3)

       International                            168,420    176,530          (4.6)
       -------------                            -------    -------

    TOTAL                                      $257,056   $268,204          (4.2)
    -----                                      --------   --------          ----

    TOTAL
     REVENUES
    ---------

       United
        States                                 $847,692   $836,535           1.3

       International                          1,204,972  1,143,995           5.3
       -------------                          ---------  ---------

    TOTAL                                    $2,052,664 $1,980,530           3.6
    -----                                    ---------- ----------           ---

    BECTON
     DICKINSON
     AND
     COMPANY

     SUPPLEMENTAL
     REVENUE
     INFORMATION

    REVENUES BY
     SEGMENT
     AND
     GEOGRAPHIC
     AREA

    (Unaudited;
     Amounts in
     thousands)

                     Nine Months Ended June 30,

                                                  2013       2012 % Change
                                                  ----       ---- --------

    BD MEDICAL
    ----------

       United
        States                              $1,286,521 $1,262,811           1.9

       International                         1,899,422  1,778,849           6.8
       -------------                         ---------  ---------

    TOTAL                                   $3,185,943 $3,041,660           4.7
    -----                                   ---------- ----------           ---

    BD
     DIAGNOSTICS
    ------------

       United
        States                                $953,143   $945,460           0.8

       International                         1,012,833    947,552           6.9
       -------------                         ---------    -------

    TOTAL                                   $1,965,976 $1,893,012           3.9
    -----                                   ---------- ----------           ---

    BD
     BIOSCIENCES
    ------------

       United
        States                                $261,693   $255,587           2.4

       International                           539,620    550,952          (2.1)
       -------------                           -------    -------

    TOTAL                                     $801,313   $806,539          (0.6)
    -----                                     --------   --------          ----

    TOTAL
     REVENUES
    ---------

       United
        States                              $2,501,357 $2,463,858           1.5

       International                         3,451,875  3,277,353           5.3
       -------------                         ---------  ---------

    TOTAL                                   $5,953,232 $5,741,211           3.7
    -----                                   ---------- ----------           ---

    BECTON DICKINSON AND
     COMPANY

    SUPPLEMENTAL REVENUE
     INFORMATION

    REVENUES BY BUSINESS
     SEGMENTS AND UNITS

    Three Months Ended
     June 30,

    (Unaudited; Amounts in
     thousands)

                              United States
                              -------------

                                                2013     2012 % Change
                                                ----     ---- --------

    BD MEDICAL
    ----------

       Medical Surgical
        Systems                             $245,869 $241,320           1.9

       Diabetes Care                         117,055  110,013           6.4

       Pharmaceutical Systems                 85,746   78,288           9.5

    TOTAL                                   $448,670 $429,621           4.4
    -----                                   -------- --------           ---

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                $167,298 $165,962           0.8

       Diagnostic Systems                    143,088  149,278          (4.1)
       ------------------                    -------  -------

    TOTAL                                   $310,386 $315,240          (1.5)
    -----                                   -------- --------          ----

    BD BIOSCIENCES                           $88,636  $91,674          (3.3)
    --------------                           -------  -------          ----

    TOTAL UNITED STATES                     $847,692 $836,535           1.3
    -------------------                     -------- --------           ---

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS

    Three Months Ended June 30, (continued)

    (Unaudited; Amounts in thousands)

                                                            International
                                                            -------------

                                                                                  % Change
                                                                                 --------

                                            2013               2012               Reported       FXN       FX Impact
                                            ----               ----              --------        ---       ---------

    BD MEDICAL
    ----------

       Medical Surgical Systems                    $315,047             $290,451            8.5      10.5            (2.0)

       Diabetes Care                                132,551              122,662            8.1      12.1            (4.0)

       Pharmaceutical Systems                       244,230              227,342            7.4       9.1            (1.7)
                                                                                                                     ----

    TOTAL                                          $691,828             $640,455            8.0      10.3            (2.3)
    -----                                          --------             --------            ---      ----            ----

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                       $177,571             $167,492            6.0       8.4            (2.4)

       Diagnostic Systems                           167,153              159,518            4.8       8.7            (3.9)
       ------------------

    TOTAL                                          $344,724             $327,010            5.4       8.6            (3.2)
    -----                                          --------             --------            ---       ---            ----

    BD BIOSCIENCES                                 $168,420             $176,530           (4.6)     (2.1)           (2.5)
    --------------                                 --------             --------           ----      ----            ----

    TOTAL INTERNATIONAL                          $1,204,972           $1,143,995            5.3       7.9            (2.6)
    -------------------                          ----------           ----------            ---       ---            ----

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS

    Three Months Ended June 30, (continued)

    (Unaudited; Amounts in thousands)

                                                             Total
                                                             -----

                                                                               % Change
                                                                              --------

                                            2013            2012               Reported       FXN       FX Impact
                                            ----            ----              --------        ---       ---------

    BD MEDICAL
    ----------

       Medical Surgical Systems                    $560,916          $531,771            5.5       6.6            (1.1)

       Diabetes Care                                249,606           232,675            7.3       9.4            (2.1)

       Pharmaceutical Systems                       329,976           305,630            8.0       9.2            (1.2)

    TOTAL                                        $1,140,498        $1,070,076            6.6       7.9            (1.3)
    -----                                        ----------        ----------            ---       ---            ----

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                       $344,869          $333,454            3.4       4.6            (1.2)

       Diagnostic Systems                           310,241           308,796            0.5       2.5            (2.0)
       ------------------

    TOTAL                                          $655,110          $642,250            2.0       3.6            (1.6)
    -----                                          --------          --------            ---       ---            ----

    BD BIOSCIENCES                                 $257,056          $268,204           (4.2)     (2.5)           (1.7)
    --------------                                 --------          --------           ----      ----            ----

    TOTAL REVENUES                               $2,052,664        $1,980,530            3.6       5.1            (1.5)
    --------------                               ----------        ----------            ---       ---            ----

    BECTON DICKINSON AND
     COMPANY

    SUPPLEMENTAL REVENUE
     INFORMATION

    REVENUES BY BUSINESS
     SEGMENTS AND UNITS

    Nine Months Ended
     June 30,

    (Unaudited; Amounts
     in thousands)

                          United States
                          -------------

                                              2013       2012 % Change
                                              ----       ---- --------

    BD MEDICAL
    ----------

       Medical Surgical
        Systems                           $730,685   $727,335          0.5

       Diabetes Care                       336,102    321,264          4.6

       Pharmaceutical
        Systems                            219,734    214,212          2.6

    TOTAL                               $1,286,521 $1,262,811          1.9
    -----                               ---------- ----------          ---

    BD DIAGNOSTICS
    --------------

       Preanalytical
        Systems                           $496,214   $491,532          1.0

       Diagnostic Systems                  456,929    453,928          0.7
       ------------------                  -------    -------

    TOTAL                                 $953,143   $945,460          0.8
    -----                                 --------   --------          ---

    BD BIOSCIENCES                        $261,693   $255,587          2.4
    --------------                        --------   --------          ---

    TOTAL UNITED STATES                 $2,501,357 $2,463,858          1.5
    -------------------                 ---------- ----------          ---

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS

    Nine Months Ended June 30, (continued)

    (Unaudited; Amounts in thousands)

                                                            International
                                                            -------------

                                                                                  % Change
                                                                                 --------

                                            2013               2012               Reported       FXN      FX Impact
                                            ----               ----              --------        ---      ---------

    BD MEDICAL
    ----------

       Medical Surgical Systems                    $904,735             $845,685            7.0       8.7           (1.7)

       Diabetes Care                                388,398              356,575            8.9      11.8           (2.9)

       Pharmaceutical Systems                       606,289              576,589            5.2       6.5           (1.3)

    TOTAL                                        $1,899,422           $1,778,849            6.8       8.6           (1.8)
    -----                                        ----------           ----------            ---       ---           ----

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                       $513,454             $481,857            6.6       8.2           (1.6)

       Diagnostic Systems                           499,379              465,695            7.2       9.6           (2.4)
       ------------------

    TOTAL                                        $1,012,833             $947,552            6.9       8.9           (2.0)
    -----                                        ----------             --------            ---       ---           ----

    BD BIOSCIENCES                                 $539,620             $550,952           (2.1)      0.2           (2.3)
    --------------                                 --------             --------           ----       ---           ----

    TOTAL INTERNATIONAL                          $3,451,875           $3,277,353            5.3       7.3           (2.0)
    -------------------                          ----------           ----------            ---       ---           ----

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    REVENUES BY BUSINESS SEGMENTS AND UNITS

    Nine Months Ended June 30, (continued)

    (Unaudited; Amounts in thousands)

                                                             Total
                                                             -----

                                                                               % Change
                                                                              --------

                                            2013            2012               Reported       FXN     FX Impact
                                            ----            ----              --------        ---     ---------

    BD MEDICAL
    ----------

       Medical Surgical Systems                  $1,635,420        $1,573,020            4.0      4.9           (0.9)

       Diabetes Care                                724,500           677,839            6.9      8.4           (1.5)

       Pharmaceutical Systems                       826,023           790,801            4.5      5.5           (1.0)

    TOTAL                                        $3,185,943        $3,041,660            4.7      5.8           (1.1)
    -----                                        ----------        ----------            ---      ---           ----

    BD DIAGNOSTICS
    --------------

       Preanalytical Systems                     $1,009,668          $973,389            3.7      4.6           (0.9)

       Diagnostic Systems                           956,308           919,623            4.0      5.2           (1.2)
       ------------------

    TOTAL                                        $1,965,976        $1,893,012            3.9      4.9           (1.0)
    -----                                        ----------        ----------            ---      ---           ----

    BD BIOSCIENCES                                 $801,313          $806,539           (0.6)     0.9           (1.5)
    --------------                                 --------          --------           ----      ---           ----

    TOTAL REVENUES                               $5,953,232        $5,741,211            3.7      4.8           (1.1)
    --------------                               ----------        ----------            ---      ---           ----

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL REVENUE INFORMATION

    SAFETY REVENUES

    (Unaudited; Amounts in thousands)

                                                      Three Months Ended June 30,
                                                   ---------------------------

                                                                                                   % Change
                                                                                                   --------

                                      2013                   2012                Reported      FXN       FX Impact
                                      ----                   ----               --------       ---       ---------

    TOTAL SAFETY REVENUES
    ---------------------

       United States                         $300,767                 $284,830             5.6      5.6               -

       International                          237,331                  215,964             9.9     12.7            (2.8)
       -------------                          -------                  -------             ---                     ----

    TOTAL                                    $538,098                 $500,794             7.4      8.7            (1.3)
    -----                                    --------                 --------             ---      ---            ----

    BY SEGMENT
    ----------

       BD Medical                            $267,782                 $240,065            11.5     12.8            (1.3)

       BD Diagnostics                         270,316                  260,729             3.7      4.8            (1.1)
       --------------                         -------                  -------             ---                     ----

    TOTAL                                    $538,098                 $500,794             7.4      8.7            (1.3)
    -----                                    --------                 --------             ---      ---            ----

                                                   Nine Months Ended June 30,
                                                   --------------------------

                                                                                                   % Change
                                                                                                   --------

                                      2013                   2012                Reported      FXN       FX Impact
                                      ----                   ----               --------       ---       ---------

    TOTAL SAFETY REVENUES
    ---------------------

       United States                         $879,079                 $858,175             2.4      2.4               -

       International                          684,630                  618,290            10.7     12.7            (2.0)
       -------------                          -------                  -------            ----                     ----

    TOTAL                                  $1,563,709               $1,476,465             5.9      6.7            (0.8)
    -----                                  ----------               ----------             ---      ---            ----

    BY SEGMENT
    ----------

       BD Medical                            $775,984                 $715,776             8.4      9.3            (0.9)

       BD Diagnostics                         787,725                  760,689             3.6      4.3            (0.7)
       --------------                         -------                  -------             ---                     ----

    TOTAL                                  $1,563,709               $1,476,465             5.9      6.7            (0.8)
    -----                                  ----------               ----------             ---      ---            ----

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    FY2013 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures

    (Unaudited)

                                                                                                                                                                Three Months Ended June 30,
                                                                                                                                                                ---------------------------

                                                                                                                                        2013       2012       Growth               Foreign Currency Translation         Foreign Currency Neutral
                                                                                                                                                                                                                                  Change               Growth %        Foreign

                                                                                                                                                                                                                                                                        Currency

                                                                                                                                                                                                                                                                        Neutral

                                                                                                                                                                                                                                                                         Growth %
                                                                                                                                                                                                                                                                          -------

    Reported Diluted Earnings per Share from Continuing Operations                                                                           $1.47      $1.52              $(0.05)                              $(0.05)                          $0.00          (3.3%)            0.0%

    Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases ($22 million or
     $14 million after-tax)                                                                                                             0.07       0.00

    Adjusted Diluted Earnings per Share from Continuing Operations                                                                            1.54       1.52               $0.02                               $(0.05)                          $0.07            1.3%            4.6%
                                                                                                                                              ----       ----               -----                               ------                           -----            ---             ---

    Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act          0.04       0.00
    ($13 million or $9 million after-tax)

    Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax                                         $1.58      $1.52               $0.06                               $(0.05)                          $0.11            3.9%            7.2%

    All figures rounded. Totals may not add due to rounding.

    BECTON DICKINSON AND COMPANY

    SUPPLEMENTAL INFORMATION

    FY2013 Year-to-Date Reconciliation of Non-GAAP Financial Measures

    (Unaudited)

                                                                                                                                                                 Nine Months Ended June 30,
                                                                                                                                                                 --------------------------

                                                                                                                                        2013       2012       Growth               Foreign Currency Translation         Foreign Currency Neutral
                                                                                                                                                                                                                                  Change               Growth %       Foreign

                                                                                                                                                                                                                                                                       Currency

                                                                                                                                                                                                                                                                       Neutral

                                                                                                                                                                                                                                                                        Growth %
                                                                                                                                                                                                                                                                         -------

    Reported Diluted Earnings per Share from Continuing Operations                                                                           $4.21      $3.95               $0.26                               $(0.05)                          $0.31           6.6%             7.8%

    Charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases ($22 million or
     $14 million after-tax)                                                                                                             0.07       0.00

    Adjusted Diluted Earnings per Share from Continuing Operations                                                                            4.28       3.95               $0.33                               $(0.05)                          $0.38           8.4%             9.6%
                                                                                                                                              ----       ----               -----                               ------                           -----           ---              ---

    Medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act          0.09       0.00
    ($27 million or $18 million after-tax)

    Adjusted Diluted Earnings per Share from Continuing Operations without Medical Device Excise Tax                                         $4.37      $3.95               $0.42                               $(0.05)                          $0.47          10.6%            11.9%

    All figures rounded. Totals may not add due to rounding.


    BECTON
     DICKINSON
     AND
     COMPANY

     SUPPLEMENTAL
     INFORMATION

    FY2013
     Outlook
     Reconciliation

                        Reported

                         Basis              FX Impact         FXN Basis
                         -----              ---------         ---------

     Revenues
     -
     Full
     Year
     2013
     estimated
     growth                     3.5% - 4.0%           (1.0%)            4.5% - 5.0%

                       Full Year            Full Year

                                       2013             2012 % Increase
                                       ----             ---- ----------

                      (estimated)

     Reported
     Fully
     Diluted
     Earnings
     per
     Share

    from
     Continuing
     Operations     $           5.65 - 5.68            $5.30     NM

     Pending
     Litigation
     Settlement
     (1)                               0.07

     Pension
     Settlement
     Charge
     (2)                                                0.06

     Adjusted
     Fully
     Diluted
     Earnings
     per
     Share

    from
     Continuing
     Operations     $           5.72 - 5.75            $5.37             6.5% - 7.0%
                                ===========            =====

    FX
     Impact                                                                    (2.0%)

     Adjusted
     FXN
     Growth                                                              8.5% - 9.0%

     Medical
     Device
     Excise
     Tax
     Impact
     (3)                                                                       (2.5%)

     Adjusted
     FXN
     Growth
     (excluding
     the
     medical
     device
     excise
     tax)                                                              11.0% - 11.5%

    (1) Represents a charge associated with the pending litigation settlement related to indirect purchaser antitrust class action cases.

    (2) Primarily represents a non-cash pension settlement charge associated with lump sum benefit payments made from the Company's

        U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year.

        The charge also included settlement losses associated with certain foreign pension plans.

    (3) Represents the medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act.

    NM - Not Meaningful

    FXN = Foreign Currency Neutral

    All figures rounded. Totals may not add due to rounding.

SOURCE BD (Becton, Dickinson and Company)


Source: PR Newswire